Eurofins Reinforces Its Specialty Clinical Diagnostics Footprint by Acquiring PerkinElmer’s NTD Laboratory Services Business
25 April 2016 - 7:00PM
Business Wire
Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA), the global leader in
bio-analytical testing, and one of the world leaders in genomic
services, announces that it has acquired PerkinElmer, Inc.’s U.S.
prenatal screening laboratory services business PerkinElmer
Labs/NTD (“NTD”).
Founded more than 30 years ago, NTD is a reference laboratory in
the US for first and second trimester prenatal screening. It has
pioneered the research and development of prenatal screening
protocols and offered the first biochemical screening test for
early onset preeclampsia. NTD’s first trimester non-invasive
prenatal screening test for Down Syndrome is the only high
sensitivity screen that uses the free Beta hCG biomarker, along
with PAPP-A and Nuchal Translucency measurement, in assessing risk
for Down syndrome.
The company generated revenues of about US$ 20m in 2015 and
employs approximately 80 staff at its laboratory in Melville, NY,
serving universities, hospitals, maternal fetal medicine
specialists, and other laboratories worldwide.
The acquisition of NTD strengthens Eurofins’ growing footprint
in the genetics segment of the specialty clinical diagnostic
testing market. NTD’s expertise in reproductive genetic testing is
fully complementary to the Group’s leading position in expanded
carrier testing capabilities, and expands Eurofins’ analytical
portfolio for genetic disorders, established through the
acquisition of Emory Genetics Laboratory (“EGL”) in 2015, a joint
venture with Emory University. The addition of NTD into Eurofins’
laboratory network further strengthens the Group’s pharmaceutical
and clinical service offering and advances its development into a
leading presence in the specialty clinical testing services for
hospitals, clinicians and pharmaceutical companies.
Comment from Dr. Gilles Martin, Eurofins CEO: “This acquisition
reflects our strategy of expanding and strengthening our network of
competence centers. NTD strengthens Eurofins’ testing capabilities
for genetic disorders, and the Group’s footprint in the specialty
clinical diagnostics market, with truly unique and innovative
services with high positive impact for patient care. In combination
with ViraCor and Diatherix for infectious diseases, Boston Heart
for cardiovascular, and EGL for genetic diseases, NTD’s expertise
in prenatal screening reinforces the Group’s position in advanced
diagnostic testing to better serve the global healthcare
community”.
For more information about Eurofins, please visit
www.eurofins.com
Notes for the editor:Eurofins – a global leader in
bio-analysis
Eurofins Scientific believes it is the world leader in food,
environment and pharmaceutical products testing, as well as one of
the global market leaders in agroscience, genomics, discovery
pharmacology and central laboratory services. In addition, Eurofins
is one of the key emerging players in specialty clinical diagnostic
testing in Europe and the USA.
With over 23,000 staff in more than 225 laboratories across 39
countries, Eurofins offers a portfolio of over 130,000 validated
analytical methods for evaluating the safety, identity,
composition, authenticity, origin, traceability and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group provides its customers with
high-quality services, accurate results on time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities and healthcare
practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:This press release contains
forward-looking statements and estimates that involve risks and
uncertainties. The forward-looking statements and estimates
contained herein represent the judgement of Eurofins Scientific’
management as of the date of this release. These forward-looking
statements are not guarantees for future performance, and the
forward-looking events discussed in this release may not occur.
Eurofins Scientific disclaims any intent or obligation to update
any of these forward-looking statements and estimates. All
statements and estimates are made based on the information
available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160425005512/en/
Eurofins Scientific GroupInvestor RelationsPhone: +32 2 766
1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024